Inceptive demonstrates improved AI-designed mRNA therapies for autoimmune conditions
The team built a lab to generate RNA data, fine-tuned its models, and achieved superior cell depletion in animal trials versus industry benchmarks.
See the latest news and media coverage for Inceptive. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI foundation model developer for drug discovery
inceptive.comLast updated
In short: Inceptive established a $2 billion partnership with Alnylam and demonstrated superior results for its AI-designed mRNA therapies.
The team built a lab to generate RNA data, fine-tuned its models, and achieved superior cell depletion in animal trials versus industry benchmarks.
Achieving B-cell depletion in vivo within weeks without training data, potentially simplifying cell therapy manufacturing and expanding patient access.
The partnership, valued at up to $2 billion, aims to use AI foundation models for oligonucleotide design.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most promising long-term stocks to buy according to analysts. On June 3, Alnylam and Inceptive Nucleics, which...
Radical Numerics is betting that the future of bio-defense and AI drug discovery lies in understandi...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration...
Track Inceptive and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Inceptive and other trending companies.